Recent news on Visipaque

PLC Presents Two Abstracts at CRT 2007  -  Mar 7, 2007
Earthtimes.orgEach received contrast doses ranging from 50 to 200 ml of Visipaque, and standard doses of Mucomyst (acetylcysteine) and sodium bicarbonate.

TCT: Low-Osmolar Contrast Agents Don't Increase Nephropathy Risk  Oct 26, 2006
26 -- The use of Visipaque (iodixanol), an iso-osmolar, nonionic contrast agent, did not reduce the rate of nephropathy in angiography patients with renal ... -MedPage Today, The Insider: Walkers can't do enough good work, VC lawyer can't ...  Nov 5, 2006
Text: Results from a recent clinical trial demonstrated that contrast agents Hexabrix(R) (Ioxaglate) and Visipaque(R) (Iodixanol) were no different in regard ... -Seattle Post Intelligencer Guerbet - Another Proof That There is no Difference Between Low ...  Oct 27, 2006
WASHINGTON, October 27 /PRNewswire/ -- Results from a recent clinical trial demonstrated that contrast agentsHexabrix(R) (Ioxaglate) and Visipaque(R) (Iodixanol ... -Earthtimes.org The Latest Head-to-Head Clinical Study Comparing the Risk of CIN ...  Nov 1, 2006
...in the United States, and Visipaque(TM)-320 (iodixanol injection), marketed by GE Healthcare in the United States, in renally Impaired Patients undergoing ... -PharmaLive.com (press release), Guerbet - Another Proof That There is no Difference Between Low ...  Oct 27, 2006
October 27 /PRNewswire/ -- Results from a recent clinical trial demonstrated that contrast agents Hexabrix® (Ioxaglate) and Visipaque® (Iodixanol) were no ... -Yahoo! News (press release) Guerbet - Another Proof That There is no Difference Between Low ...  Oct 27, 2006
October 27, 2006 /PRNewswire/ -- Results from a recent clinical trial demonstrated that contrast agents Hexabrix(R) (Ioxaglate) and Visipaque(R) (Iodixanol ... -PharmaLive.com (press release), GE Healthcare Collaborates With Manipal Health Systems to Conduct ...  Jun 29, 2006
The first studies will focus on Visipaque(TM) (iodixanol) an isosmolar contrast agent that was launched globally by GE Healthcare in 1996. ... -Juraforum.de

COMUNICADO: GE Healthcare Collaborates With Manipal Health Systems ...  Jun 29, 2006
In the United States: Visipaque is not for Intrathecal Use. ... Manifest thyrotoxicosis. History of serious hypersensitivity reaction to Visipaque. ... -Europa Press

GE ties up with Manipal Hospital for clinical trials  Jun 29, 2006
The first studies will focus on Visipaque (iodixanol) an isosmolar contrast agent that was launched globally by GE Healthcare in 1996. ... -domain-B

GE Healthcare's 1st clinical studies centre in B'lore  Jun 29, 2006
...technology. The first study will focus on Visipaque, a contrast agent that was launched globally by GE Healthcare in 1996. Contrast ... -Business Standard

GE Healthcare ties up with Manipal Hospital  Jun 30, 2006
The first studies would focus on Visipaque, an X-Ray/CT product for diagnosis of a wide range of diseases, including coronary heart disease, and aid in stent ... -Hindu

GE Healthcare to conduct clinical trials in India  Jun 29, 2006
MHS director and CEO R. Basil said the first studies would focus on Visipaque, an isosmolar contrast agent, used in X-ray and computer tomography (CT ... -DailyIndia.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional